CCCC – c4 therapeutics, inc. (US:NASDAQ)

News

C4 Therapeutics (CCCC) had its "overweight" rating reaffirmed by Barclays PLC.
C4 Therapeutics (CCCC) had its "buy" rating reaffirmed by TD Cowen.
C4 Therapeutics beats Q4 street views [Seeking Alpha]
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com